Le Lézard
Classified in: Business
Subject: ATY

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Reckitt Benckiser Group plc; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RBGLY


NEW YORK, July 18, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reckitt Benckiser Group plc (OTC: RBGLY) from July 28, 2014 through April 9, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Reckitt investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Reckitt class action, go to http://www.rosenlegal.com/cases-register-1622.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug's purportedly superior efficacy and safety as compared to tablets; (2) contrary to defendants' public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (3) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (4) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (5) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug's abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (6) as a result, Reckitt's revenues, net income and earnings were artificially inflated and the product of illicit business practices; (6) Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties; and (7) as a result, defendants' statements about Reckitt's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 13, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1622.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.   Rosen Law Firm has secured hundreds of millions of dollars for investors. 

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

 

SOURCE Rosen Law Firm, P.A.


These press releases may also interest you

at 04:00
Raymond James has appointed Allan Bertie as co-head of its European Investment Banking practice. Bertie will co-lead the firm's fast-growing European investment banking practice alongside current Head of European Investment banking and Chief...

at 04:00
Covantis, the industry initiative that aims to modernize global trade operations, announced today it has received all required regulatory approvals and has incorporated as a legal entity in Geneva, Switzerland, as Covantis SA. The company is co-owned...

at 04:00
With over 70 million new articles written each month, and 27 million shared digitally each day (Brandwatch), marketers, influencers and thought leaders need help to cut through the noise and curate quality content.  Two companies, Zest and UpContent,...

at 04:00
Karina Pismichenko knows that medical professionals, such as family physicians, are not only some of the most needed types of physicians in the U.S., but are also ones that need help from medical billers frequently. These physicians are always...

at 03:52
- Together with Futur/io, Wirecard launches the 'Innovation for Now' platform where merchants can find assistance packages from leading companies like SAP and Wirecard - Wirecard offers a range of low-cost solutions for affected merchants that want...

at 03:38
Coor has delivered facility management services to five of Equinor's oil platforms since 2015. Equinor has chosen to extend the agreement by three years by exercising an option under the contract. The agreement is worth just under SEK 200 M annually....



News published on 18 july 2019 at 14:28 and distributed by: